Skip to main content

This is a preprint.

It has not yet been peer reviewed by a journal.

The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed.

bioRxiv logoLink to bioRxiv
[Preprint]. 2023 Sep 17:2023.02.27.530277. Originally published 2023 Feb 28. [Version 2] doi: 10.1101/2023.02.27.530277

Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes

Brenda Kapingidza, Daniel J Marston, Caitlin Harris, Daniel Wrapp, Kaitlyn Winters, Dieter Mielke, Lu Xiaozhi, Qi Yin, Andrew Foulger, Rob Parks, Maggie Barr, Amanda Newman, Alexandra Schäfer, Amanda Eaton, Justine Mae Flores, Austin Harner, Nicholas J Cantazaro, Michael L Mallory, Melissa D Mattocks, Christopher Beverly, Brianna Rhodes, Katayoun Mansouri, Elizabeth Van Itallie, Pranay Vure, Brooke Manness, Taylor Keyes, Sherry Stanfield-Oakley, Christopher W Woods, Elizabeth A Petzold, Emmanuel B Walter, Kevin Wiehe, Robert J Edwards, David Montefiori, Guido Ferrari, Ralph Baric, Derek W Cain, Kevin O Saunders, Barton F Haynes, Mihai L Azoitei
PMCID: PMC10002628  PMID: 36909627

Abstract

Immune responses to SARS-CoV-2 primarily target the receptor binding domain of the spike protein, which continually mutates to escape acquired immunity. Other regions in the spike S2 subunit, such as the stem helix and the segment encompassing residues 815-823 adjacent to the fusion peptide, are highly conserved across sarbecoviruses and are recognized by broadly reactive antibodies, providing hope that vaccines targeting these epitopes could offer protection against both current and emergent viruses. Here we employed computational modeling to design scaffolded immunogens that display the spike 815-823 peptide and the stem helix epitopes without the distracting and immunodominant RBD. These engineered proteins bound with high affinity and specificity to the mature and germline versions of previously identified broadly protective human antibodies. Epitope scaffolds interacted with both sera and isolated monoclonal antibodies with broadly reactivity from individuals with pre-existing SARS-CoV-2 immunity. When used as immunogens, epitope scaffolds elicited sera with broad betacoronavirus reactivity and protected as “boosts” against live virus challenge in mice, illustrating their potential as components of a future pancoronavirus vaccine.

Full Text Availability

The license terms selected by the author(s) for this preprint version do not permit archiving in PMC. The full text is available from the preprint server.


Articles from bioRxiv are provided here courtesy of Cold Spring Harbor Laboratory Preprints

RESOURCES